Table 1.
Key proteoglycans organized per class, with cellular source(s), and selected functional roles indicated
Proteoglycan | Expression | Source(s) | Functional Role(s) | References |
---|---|---|---|---|
Serglycin | Intracellular | Immune cells, endothelial cells, fibroblasts, chondrocytes, smooth muscle cells, fetal liver, nasopharyngeal, and hematopoietic cancer cells | Complexes with and modulates the activities of mast cell proteases, e.g., chymases, tryptases, and carboxypeptidase A; acts as a vehicle for delivery of granzyme B in cytotoxic cells; triggers CD44 signaling in tumor cells; regulates IL-8 secretion in cancers; via tumor-derived exosomes, it protects human multiple myeloma from complement attack by binding C1q and MBL in the TME | 21, 22–24, 25–42 |
Syndecan-1 | Cell surface | Normal and malignant plasma cells; normal and malignant epithelial cells | Sequesters T-cell specific CC-chemokines, and in soluble form, with VEGFR2 and VLA-4; On the cell surface, engages CXCR4, VLA-4, and VEGFR2; upregulates IL-23 and Notch ligand DLL4, which polarizes CD4+ T cells toward the Treg, Th17, and Th1 phenotypes | 21, 43–56, 57–64 |
Syndecan-2 | Cell surface | Mesenchymal cells, tumor-associated stromal cells | Modulates TFG-β signaling to control tumorigenesis via TFG-β-induced genes PD-L1 and CXCR4 in TASC | 21, 43–56, 65 |
Syndecan-3 | Cell surface | Neuronal tissue; tumor-associated macrophages; tumor endothelial cells; bladder, prostate, breast, and pancreatic cancer cell lines | Accentuates the IFN-γ-regulome, including upregulation of CD274 and CD8; regulates hypoxia-resistance in a HIF1α-dependent manner | 21, 43–56, 66,67 |
Syndecan-4 | Cell surface | Ubiquitous expression | Ligand for dendritic cell-associated heparan sulfate proteoglycan-integrin ligand (DC-HIL) to attenuate T-cell activation; sequesters TFG-β on the cell surface | 21, 43–56, 68–72 |
Chondroitin sulfate proteoglycan 4 | Cell surface | Monocytes/macrophages | Activates monocytes to secrete IL-1β and induce monocyte-dependent B cell proliferation in vitro | 21, 73–75 |
Betaglycan | Cell surface | Ubiquitous expression | Accentuates TGF-β signaling or interferes with TGF-β receptor type I and TGF- β receptor type II complexing; in soluble form, can sequester TGF-β; upregulates Cdc42 via β-arrestin-2 in vivo | 76–81 |
Glypican-1 | Cell surface | Ubiquitous expression | FGF signaling; PTEN attenuation; Akt and β-catenin signaling; recognition by NK cells via NKp46 and NKp30; interacts with VEGF via HS chains | 21, 82, 83, 84 |
Glypican-2 | Cell surface | Embryonic central nervous system tissue; neuroblastoma cells | Upregulates expression of N-Myc, which in turn promotes transcription of the glypican-2 in a positive feedback loop | 21, 82, 83 |
Glypican-3 | Cell surface | Ovary, breast, lung, and kidney epithelial cells | Sequesters VEGF in TME; inhibits Zeb1 transcription factor; influences PI3K/Akt, p38, ERK1/2, and Wnt signaling pathways (context dependent); induces cytotoxic T-cell and macrophage recruitment in HCC | 21, 82, 83, 85–87 |
Glypican-4 | Cell surface | Ubiquitous expression | Accentuates Wnt signaling and pluripotency; reduces sensitivity of pancreatic cancer cells to 5-fluorouracil | 21, 82, 83 |
Glypican-5 | Cell surface | Central nervous system | Acts through FGF, HGF, and Wnt1α to promote cell division; tumor suppressor in certain contexts, e.g., glioma | 21, 82, 83 |
Glypican-6 | Cell surface | Gallbladder, urinary bladder, liver, appendix, and kidney epithelial cells | CD8A mRNA transcription; Wnt signaling modulation; tumor infiltration of cytotoxic T-cells | 21, 82, 83, 88 |
Perlecan | Pericellular | Stromal cells | Sequesters bioactive molecules (via GAG chains) | 21, 89–93 |
Agrin | Pericellular | Stromal cells | Activates VEGF-VEGFR2 pathway; stimulates angiogenesis | 21, 94 |
Biglycan | Extracellular | Stromal cells; macrophages; immune cells | Binds TLR2/4; forms complexes with CD14-TLR4 and P2X4/P2X7 respectively; promotes tumor progression | 95, 96–104, 105 |
Decorin | Extracellular | Stromal cells | Binds TLR2/4; sequesters TGF-β; upregulates PDCD4; inhibits tumor growth | 95, 105–107 |
Lumican | Extracellular | Stromal cells | Enhances LPS-dependent TLR4 signaling; tumor-dependent impact on EMT, immune infiltration and inflammation | 21, 97, 108–110 |
Versican | Extracellular | Stromal cells; myeloid cells | Binds hyaluronan, P and L selectins, CD44, and TLR2; promotes accumulation of tumor-associated macrophages and decrease intraepithelial tumor infiltrating lymphocytes; positively correlated with Th2 and Treg transcriptional signatures, negatively correlated with cytotoxic T-cell signatures | 22, 10–13, 111–148 |
Aggrecan | Extracellular | Cartilage and perineural net stromal cells | Forms aggregates for load-bearing structural support and mechanical properties to joints; protects neurons via cation sequestration and mechanically stabilization of synaptic connections | 21 |
Brevican | Extracellular | Neural tissue stromal cells | Interacts with tenascin-R and fibulin-2; neural tissue injury and repair, Alzheimer’s disease, glioma tumorigenesis | 21 |
Neurocan | Extracellular | Neural tissue stromal cells | Alleviates mechanical and ischemic damage in central nervous system; inhibits neurite outgrowth in vivo; assists in neural guidance during development | 21 |
Hyaluronan and proteoglycan link protein 1 | Extracellular | Stromal cells | Binds to aggrecan complexes in cartilage to offer structural support; NF-κB pathway activation; myeloma drug resistance | 149–153 |